GlaxoSmithKline PLC (GSK) Position Held by Smithfield Trust Co.

Smithfield Trust Co. held its stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, Holdings Channel reports. The firm owned 2,391 shares of the pharmaceutical company’s stock at the end of the second quarter. Smithfield Trust Co.’s holdings in GlaxoSmithKline PLC were worth $103,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Integrated Wealth Management purchased a new stake in GlaxoSmithKline PLC during the first quarter worth $208,000. Atria Investments LLC increased its stake in GlaxoSmithKline PLC by 1.8% in the first quarter. Atria Investments LLC now owns 16,523 shares of the pharmaceutical company’s stock worth $697,000 after buying an additional 290 shares during the last quarter. Winslow Evans & Crocker Inc. increased its stake in GlaxoSmithKline PLC by 4.7% in the first quarter. Winslow Evans & Crocker Inc. now owns 7,754 shares of the pharmaceutical company’s stock worth $327,000 after buying an additional 350 shares during the last quarter. TNB Financial purchased a new stake in GlaxoSmithKline PLC during the first quarter worth $1,790,000. Finally, Capstone Asset Management Co. increased its stake in GlaxoSmithKline PLC by 6.7% in the first quarter. Capstone Asset Management Co. now owns 102,668 shares of the pharmaceutical company’s stock worth $4,328,000 after buying an additional 6,420 shares during the last quarter. Institutional investors and hedge funds own 8.96% of the company’s stock.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 39.53 on Thursday. The company has a 50 day moving average price of $42.13 and a 200 day moving average price of $41.86. The company has a market capitalization of $96.61 billion, a PE ratio of 38.23 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a dividend yield of 4.97%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 194.00%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Position Held by Smithfield Trust Co.” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/2796238/glaxosmithkline-plc-gsk-position-held-by-smithfield-trust-co.html.

A number of equities research analysts have weighed in on the company. ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Friday, June 16th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Citigroup Inc. downgraded GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. Finally, Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.